https://www.prnewswire.com/news-releases/nuvalent-announces-initiation-of-alkazar-phase-3-randomized-controlled-trial-evaluating-neladalkib-for-patients-with-tki-naive-alk-positive-nsclc-302508977.html
Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...
randomized controlled trial
https://www.prnewswire.com/news-releases/nuvalent-presents-preliminary-data-for-neladalkib-in-advanced-alk-positive-solid-tumors-beyond-nsclc-at-esmo-2025-302588111.html
Nuvalent Presents Preliminary Data for Neladalkib in Advanced ALK-positive Solid Tumors Beyond...
/PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically...